文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

外科ICU患者中优化持续输注哌拉西林-他唑巴坦与美罗培南的病原体为基础的目标达成:前瞻性单中心观察性研究

Pathogen-based target attainment of optimized continuous infusion dosing regimens of piperacillin-tazobactam and meropenem in surgical ICU patients: a prospective single center observational study.
PubMed 文献 · Ann Intensive Care · 2023-04-29
一句话结论外科ICU优化持续输注TZP与MEM时,病原体为基础的目标达成率虽高于理论最差情况,但相当比例样本仍未达常用PK/PD目标。

该前瞻性单中心观察性研究于2016年3月至2019年4月纳入781例外科ICU患者,共1036次β-内酰胺类抗菌药物处方(731次TZP,305次MEM),分析2810份血药浓度样本。TZP校正后中位血浆浓度为86.4 mg/L(IQR 56.2-148),MEM为16.2 mg/L(IQR 10.2-25.5)。病原体为基础的临床相关目标达成(CRTA)与治疗范围达成(TRA)均持续高于最差情况场景,但相当比例样本仍未达常用PK/PD目标。作者认为,在评估目标达成及临床结局时,病原体为基础的分析方法可能比最差情况场景更合理,并提示需更多剂量优化研究。

要点

  • 外科ICU患者优化持续输注TZP与MEM时,TZP校正后中位血浆浓度86.4 mg/L(IQR 56.2-148),MEM为16.2 mg/L(IQR 10.2-25.5)。
  • 病原体为基础的CRTA与TRA持续高于最差情况场景(TZP 16 mg/L、MEM 2 mg/L),但相当比例样本仍未达常用PK/PD目标。
  • TZP治疗范围上限设为157.2 mg/L,MEM为45 mg/L,用于评估TRA。
  • 作者认为,评估目标达成及临床结局时,病原体为基础的分析方法可能比最差情况场景更合理。
  • 作者认为,优化持续输注方案下仍有相当比例样本未达标,需更多剂量优化研究。

适用人群与场景

  • 外科ICU患者,2016年3月至2019年4月单中心前瞻性观察。
  • 纳入781例独特患者,1036次β-内酰胺类抗菌药物处方(731次TZP,305次MEM),对应1003次独特感染/预防方案(750次TZP,323次MEM)。

诊断标准与关键阈值

  • CRTA定义为校正后实测总血清浓度高于病原体折点(BP),BP由流行病学cut-off值推导,并计算至6倍BP的递增BP倍数。
  • TRA上限:TZP为157.2 mg/L,MEM为45 mg/L。
  • 最差情况场景BP:TZP为16 mg/L,MEM为2 mg/L。

处置流程与药物剂量

  • TZP与MEM均采用优化持续输注给药方案(具体剂量、输注时长原文未写明)。
  • 游离血浆浓度通过校正总血浆浓度(基于血气样本残液,采用超高效液相色谱-串联质谱测定)的蛋白结合率计算。

研究设计与关键结果

  • 研究类型:前瞻性单中心观察性研究;样本量781例患者、1036次处方、1003次感染/预防方案、2810份样本(1892份TZP,918份MEM)。
  • TZP校正后中位血浆浓度86.4 mg/L(IQR 56.2-148),MEM为16.2 mg/L(IQR 10.2-25.5)。
  • 病原体为基础的CRTA与TRA持续高于最差情况场景,但相当比例样本未达常用PK/PD目标。

证据类型、等级与局限

  • 证据类型:前瞻性单中心观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在评估目标达成及临床结局时,病原体为基础的分析方法可能比最差情况场景更合理。
  • 作者认为,优化持续输注方案下仍有相当比例样本未达常用PK/PD目标,需更多剂量优化研究。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Several studies have indicated that commonly used piperacillin-tazobactam (TZP) and meropenem (MEM) dosing regimens lead to suboptimal plasma concentrations for a range of pharmacokinetic/pharmacodynamic (PK/PD) targets in intensive care unit (ICU) patients. These targets are often based on a hypothetical worst-case scenario, possibly overestimating the percentage of suboptimal concentrations. We aimed to evaluate the pathogen-based clinically relevant target attainment (CRTA) and therapeutic range attainment (TRA) of optimized continuous infusion dosing regimens of TZP and MEM in surgical ICU patients.

METHODS: A single center prospective observational study was conducted between March 2016 and April 2019. Free plasma concentrations were calculated by correcting total plasma concentrations, determined on remnants of blood gas samples by ultra-performance liquid chromatography with tandem mass spectrometry, for their protein binding. Break points (BP) of identified pathogens were derived from epidemiological cut-off values. CRTA was defined as a corrected measured total serum concentration above the BP and calculated for increasing BP multiplications up to 6 × BP. The upper limit of the therapeutic range was set at 157.2 mg/L for TZP and 45 mg/L for MEM. As a worst-case scenario, a BP of 16 mg/L for TZP and 2 mg/L for MEM was used.

RESULTS: 781 unique patients were included with 1036 distinctive beta-lactam antimicrobial prescriptions (731 TZP, 305 MEM) for 1003 unique infections/prophylactic regimens (750 TZP, 323 MEM). 2810 samples were available (1892 TZP, 918 MEM). The median corrected plasma concentration for TZP was 86.4 mg/L [IQR 56.2-148] and 16.2 mg/L [10.2-25.5] for MEM. CRTA and TRA was consistently higher for the pathogen-based scenario than for the worst-case scenario, but nonetheless, a substantial proportion of samples did not attain commonly used PK/PD targets.

CONCLUSION: Despite these pathogen-based data demonstrating that CRTA and TRA is higher than in the often-used theoretical worst-case scenario, a substantial proportion of samples did not attain commonly used PK/PD targets when using optimised continuous infusion dosing regimens. Therefore, more dosing optimization research seems warranted. At the same time, a 'pathogen-based analysis' approach might prove to be more sensible than a worst-case scenario approach when evaluating target attainment and linked clinical outcomes.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. De Corte T, Verhaeghe J, Dhaese S, et al. Pathogen-based target attainment of optimized continuous infusion dosing regimens of piperacillin-tazobactam and meropenem in surgical ICU patients: a prospective single center observational study. Ann Intensive Care. 2023. PMID: 37119362. doi:10.1186/s13613-023-01129-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。